TICKERNERD
Menu
VIVSVIVSHealthcare · Biotechnology

VIVS Stock Forecast: VivoSim Labs, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$0.27
−2.68% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 14 Sept 2026 — in the lower half.

Market cap
$3.8M
Ticker Nerd rank
33 / 100
Median analyst target
—
Analysts covering
—
Revenue$18K−51.4% y/y
Operating income−$2.8M
Net income−$1.3M
Free cash flow−$3.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.7%
1M
−14.8%
YTD
−84.9%
1Y
−94.3%
From 52W high
−94.3%
From 52W low
0.0%
$0.27
$4.78
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VIVS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores VivoSim Labs, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Sept 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Accruals
89
Issuance
64
Growth
38
Quality
33
Volatility
27
Revisions
25
Momentum
22
Value
10

Size (96): Smaller than most of the companies we track.

Value (10): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VIVS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VIVS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$1.00$2.00$3.00$4.00$5.00Oct 25Jan 26Apr 26Jul 26VIVS

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VIVS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VIVS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, VivoSim Labs, Inc. returned −94.3% against +16.4% for the S&P 500, dividends included.

VIVS vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Oct 25Jan 26Apr 26Jul 26VIVSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VIVS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

VivoSim Labs, Inc. (VIVS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.5×

Cheaper than 71% of US stocks

Price / sales
33.8×

Cheaper than 7% of US stocks

Price / book
0.2×

Cheaper than 90% of US stocks

EV / EBITDA
−0.3×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
−51.4%

Higher than 5% of US stocks

Earnings growth (YoY)
−51.4%

Higher than 10% of US stocks

Gross margin
100.0%

Higher than 99% of US stocks

Operating margin
−15327.8%

Higher than 1% of US stocks

Net margin
100.0%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−343.1%

Higher than 5% of US stocks

Return on assets
−89.5%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

VivoSim Labs, Inc. (VIVS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • VivoSim Labs, Inc. has a market value of $3.8M and an enterprise value of $2.9M.

  • Revenue in the twelve months to 30 June 2026: $112K. The latest quarter shrank 51.4% year on year.

  • Net income over the same four quarters: −$12.3M, a −11016.1% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$10.1M.

  • Shares outstanding: 3.2M.

  • Trailing P/E: 0.5×.

  • VivoSim Labs, Inc. employs 15 people — $7K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

VIVS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VIVSVivoSim Labs, Inc.$3.8M
33
DRMADermata Therapeutics, Inc.$4.6M
27
LIMNLiminatus Pharma, Inc.$4.7M
11
JUNSJupiter Neurosciences, Inc.$4.5M
10
HCWBHCW Biologics Inc.$4.9M
63
LABTLakewood-Amedex Biotherapeutics, Inc.$5.0M
21
MLECMoolec Science SA$5.2M
3

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own VivoSim Labs, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VIVS news & analysis

VivoSim Labs to Add Rat Liver Model to NAMkind Platform

GlobeNewsWire · 1 Sept 2026positive

VivoSim Labs announced it is adding a rat liver model to its NAMkind platform, a new cross-species capability designed to help pharmaceutical companies distinguish rat-specific liver toxicity from risks that may translate to humans.

Why it matters — This expands the platform's offerings to help drug developers better assess liver toxicity risk across species, potentially strengthening VivoSim's value proposition in preclinical safety testing.

VivoSim Provides Financial and Listing Compliance Update

GlobeNewsWire · 6 Aug 2026positive

VivoSim Labs announced it received notice from Nasdaq on August 4, 2026 that it regained compliance with Listing Rule 5550(b)(1), which requires minimum stockholders' equity of $2.5 million. This followed a $5.0 million milestone payment from Eli Lilly and a $1.0 million escrow release, both tied to the prior sale of its FXR program.

Why it matters — Regaining compliance removes a near-term delisting risk for VIVS, which was addressed through newly received funds from its Eli Lilly FXR program transaction.

FAQ

Frequently asked questions about VIVS stock

How does Ticker Nerd's model rank VIVS?

As at 14 Sept 2026, VivoSim Labs, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the VIVS stock forecast for 2030?

No analyst covering VivoSim Labs, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VIVS are extrapolating price history, which says nothing about the business.

How has VIVS stock performed over the past year?

VivoSim Labs, Inc. returned -94.3% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does VivoSim Labs, Inc. do?

VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine.

What is the latest news on VIVS?

The most recent item we track (GlobeNewsWire, 1 Sept 2026): "VivoSim Labs to Add Rat Liver Model to NAMkind Platform". VivoSim Labs announced it is adding a rat liver model to its NAMkind platform, a new cross-species capability designed to help pharmaceutical companies distinguish rat-specific liver toxicity from risks that may translate to humans.

Company

About VivoSim Labs, Inc.

VivoSim Labs Inc. is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The company provides human-relevant toxicology insights through its new approach methodologies, including customizable NAMkind™ models designed to evaluate liver toxicity, intestinal toxicity, permeability, and related drug properties. VivoSim Labs also supports investigational toxicology, mechanism-of-action studies, predictive screening, and research services for pharmaceutical and biotechnology partners at different stages of drug development. Based in San Diego, California, VivoSim Labs plays a specialized role in preclinical testing by using complex human tissue systems to help researchers study drug behavior in a more biologically relevant environment.

15 employees · United States · https://vivosim.ai